International Journal of Multidisciplinary Research and Growth Evaluation.

Economic Impact of Early Detection Programs for Cardiovascular Disease

Tarilate Temedie-Asogwa [1], Julie Alaere Atta [2*], Mohammad Ahmmad Mahmoud Al Zoubi [3], Joy Amafah [4]
[1] University of Houston, Houston, Texas, USA
[2] The University of Texas Health Science Center at Houston (UTHealth), Houston, Texas, USA
[3] The University of Texas Health Science Center at Houston (UTHealth), Houston, Texas, USA
[4] Universidad Central de Nicaragua, Nicaragua

* Corresponding Author: **Julie Alaere Atta**

Article Info

ISSN (online): 2582-7138
Volume: 05
Issue: 01
January-February 2024
Received: 06-12-2023
Accepted: 05-01-2024
Page No: 1272-1281

Abstract
Cardiovascular disease (CVD) remains a leading cause of morbidity and mortality worldwide, imposing significant economic burdens on healthcare systems and economies. Early detection programs, which involve screening, diagnostic testing, and risk assessment, play a crucial role in reducing the prevalence and severity of CVD. This review examines the economic impact of early detection programs by analyzing their cost-effectiveness, potential savings in healthcare expenditures, and broader economic benefits. Early detection allows for timely interventions that reduce hospitalizations, emergency care visits, and the need for costly treatments such as surgeries and long-term medication. Preventive measures, including lifestyle modifications and early pharmacological interventions, have been shown to lower the incidence of severe cardiovascular events, thereby reducing direct healthcare costs. Additionally, early detection programs contribute to improved workforce productivity by preventing premature deaths and reducing disability-related work absences. Despite these benefits, challenges exist in implementing large-scale early detection programs. High initial costs, accessibility barriers, and disparities in healthcare infrastructure can limit their effectiveness, particularly in low-income regions. Moreover, compliance with screening recommendations and follow-up care remains a concern. Addressing these challenges requires strong policy support, increased funding, and technological innovations such as AI-driven diagnostics and digital health monitoring. This review also presents case studies of successful early detection initiatives and their economic outcomes. The findings suggest that investing in early detection programs can lead to long-term cost savings and improved public health outcomes. Policymakers and healthcare stakeholders must prioritize these programs to create sustainable healthcare models that reduce the financial burden of CVD while enhancing population health.

DOI: https://doi.org/10.54660/.IJMRGE.2024.5.1-1272-1281

Keywords: Economic, Early detection, Cardiovascular disease, Review.

1. Introduction

Cardiovascular disease (CVD) is a leading cause of death and disability worldwide, contributing significantly to the global burden of disease (Avwioroko, 2023) [7]. This group of disorders includes conditions affecting the heart and blood vessels, such as coronary artery disease, heart failure, stroke, and peripheral artery disease. According to the World Health Organization (WHO), CVDs are responsible for an estimated 17.9 million deaths annually, representing approximately 31% of global mortality (Adegoke *et al*., 2022) [1]. The prevalence of CVD is rising due to factors such as aging populations, urbanization, sedentary lifestyles, poor diet, and the increasing incidence of risk factors like hypertension, diabetes, and obesity. This growing burden places a significant strain on healthcare systems worldwide, highlighting the urgent need for effective prevention and management strategies (Avwioroko, 2023) [8].

The importance of early detection in mitigating the impact of CVD cannot be overstated. Early identification of individuals at

high risk for cardiovascular events allows for timely intervention, which can substantially reduce both mortality and morbidity (Nnagha *et al*., 2023) [29]. Risk factors such as high cholesterol, hypertension, and smoking are well-known contributors to CVD, but often these conditions remain undiagnosed until they progress to more severe stages. The development of non-invasive, cost-effective screening tools and diagnostic technologies has the potential to enable earlier detection, allowing for the implementation of preventive measures before the onset of life-threatening complications (Avwioroko, 2023) [9]. By addressing CVD at an early stage, healthcare providers can significantly reduce the incidence of stroke, myocardial infarction, and other serious cardiovascular events, ultimately improving public health outcomes and quality of life (Matthew *et al*., 2024) [1].

The objectives of this review are to explore the current state of early detection methods for cardiovascular disease, examining the various diagnostic technologies and screening approaches that are available today. The review will also highlight the effectiveness of these strategies in identifying individuals at risk and reducing the long-term impact of CVD. Furthermore, the review will consider emerging technologies and future directions in the field, with a focus on personalized medicine and the role of biomarkers in enhancing the precision of early detection. By synthesizing current research and clinical practices, this review aims to provide insights into how early detection can be optimized to reduce the global burden of cardiovascular disease and improve patient outcomes.

2. Methodology

The PRISMA methodology is a comprehensive framework used to guide systematic reviews and meta-analyses, ensuring transparency and reproducibility. In examining the economic impact of early detection programs for cardiovascular disease (CVD), the PRISMA guidelines provide a structured approach to collecting, analyzing, and presenting relevant data. This systematic review follows the PRISMA framework to assess the effectiveness, cost-effectiveness, and economic benefits of early detection strategies in reducing the financial burden of CVD.

To begin, a comprehensive search strategy was developed to identify studies examining the economic impact of early detection programs for CVD. Relevant databases, including PubMed, Scopus, Web of Science, and Cochrane Library, were searched using a combination of keywords such as "early detection," "cardiovascular disease," "economic impact," "cost-effectiveness," and "screening programs." Both observational and interventional studies published in peer-reviewed journals were considered for inclusion. Articles were selected based on predefined eligibility criteria, focusing on studies that addressed economic evaluations, cost-effectiveness analyses, or economic modeling of early detection methods for CVD.

A critical aspect of this review was the inclusion of studies that reported economic outcomes related to early detection programs. These outcomes included direct costs (e.g., screening, diagnostic tests, treatments), indirect costs (e.g., lost productivity, long-term care), and overall economic benefits (e.g., reduction in hospitalizations, mortality, or long-term care costs). Studies that assessed the implementation of different detection strategies, such as routine screening for risk factors like hypertension and high cholesterol, as well as more advanced diagnostic techniques (e.g., imaging technologies, biomarkers), were considered.

After identifying relevant studies, data extraction was performed by two independent reviewers to ensure accuracy and consistency. Information collected included study design, population characteristics, type of early detection program, economic outcomes, and key findings related to the cost-effectiveness or economic benefits of early intervention. In cases where discrepancies arose in the data extraction process, consensus was reached through discussion or consultation with a third reviewer.

The quality and risk of bias of the included studies were assessed using standard appraisal tools. For economic evaluations, the Drummond checklist was employed to assess the methodological rigor of cost-effectiveness analyses and other economic studies. This tool provided a systematic evaluation of the study's design, data sources, costing methods, and assumptions. The risk of bias in individual studies was also assessed using the Cochrane Risk of Bias tool for randomized controlled trials and the ROBINS-I tool for non-randomized studies.

The synthesized data from the included studies were analyzed to determine the economic impact of early detection programs for CVD. Quantitative analysis was conducted where appropriate, including a cost-effectiveness analysis and a calculation of the incremental cost-effectiveness ratio (ICER) to assess the economic efficiency of early detection interventions. When possible, subgroup analyses were performed based on factors such as age, risk profile, and healthcare setting to identify which groups might benefit most from early detection programs. Qualitative analysis was used to summarize findings on the economic outcomes of early detection, including cost savings, reduced hospital admissions, and long-term healthcare cost reductions.

Finally, the findings were interpreted in the context of the existing literature, with an emphasis on understanding the broader economic implications of implementing early detection programs at the population level. The review also considered the challenges and limitations of current economic evaluations, including the variability in study designs, healthcare settings, and the quality of cost data. A discussion of the policy implications of these findings was provided, highlighting the potential for early detection programs to reduce the overall economic burden of CVD and improve the sustainability of healthcare systems.

This PRISMA-guided review aims to provide a comprehensive and transparent synthesis of the economic impact of early detection programs for cardiovascular disease, offering valuable insights for policymakers, healthcare providers, and researchers.

2.1 The Economic Burden of Cardiovascular Disease

Cardiovascular disease (CVD) is a leading cause of morbidity and mortality worldwide, with profound implications for both individual health and the global economy. As the prevalence of CVD continues to rise, its economic burden has become an increasing concern for healthcare systems, governments, and societies at large (Avwioroko and Ibegbulam, 2024) [10]. The economic impact of CVD can be classified into two main categories: direct costs and indirect costs. Together, these costs highlight the significant financial strain CVD imposes, not only on healthcare systems but also on productivity, quality of life, and economic stability across different countries.

Direct costs associated with CVD primarily stem from healthcare expenditures, including hospitalizations, medical treatments, diagnostic services, and long-term medication costs (Mela *et al*., 2020) [27]. The healthcare costs of CVD are substantial, encompassing expenses related to hospital admissions, outpatient visits, diagnostic testing, surgical interventions, and rehabilitation services (Al Hasan *et al*.,

2024) [6]. Hospitalization represents a significant portion of these direct costs, as individuals with severe cardiovascular conditions such as heart attacks, strokes, or heart failure require intensive care and extended stays in medical facilities. In high-income countries, the cost of hospital care for CVD patients can account for a large portion of national healthcare budgets, particularly in the treatment of acute events and complications. Medications play a pivotal role in the management of CVD, especially for chronic conditions like hypertension, hyperlipidemia, and heart failure. Long-term drug therapies, such as statins, beta-blockers, and anticoagulants, are critical for controlling risk factors and preventing disease progression. However, these medications come with a high financial burden, both for patients and healthcare systems. The need for ongoing pharmacological treatment, coupled with the costs of monitoring and follow-up care, adds to the financial strain of CVD management. Additionally, diagnostic procedures such as imaging (e.g., echocardiograms, angiograms) and laboratory tests (e.g., lipid panels, blood pressure monitoring) contribute to the direct costs associated with CVD (Matthew *et al*., 2024) [2]. The complexity and frequency of these procedures increase the overall financial burden on both healthcare providers and patients.

Indirect costs of CVD include the economic impact of lost productivity, disability, and premature mortality. CVD significantly affects individuals' ability to work and contribute to the economy, especially among middle-aged and older populations (Okpujie *et al*., 2024) [34]. Workers with CVD may experience long periods of absenteeism due to hospitalization, medical treatments, or recovery from cardiovascular events. Chronic conditions like heart failure or post-stroke rehabilitation can lead to long-term disability, further reducing individuals' productivity. This loss of labor force participation not only impacts the affected individuals but also has broader economic consequences, as businesses experience reduced output and governments bear the burden of welfare and disability payments. Premature mortality is another significant contributor to the indirect costs of CVD. Individuals who die from CVD-related events before reaching retirement age often leave behind a loss in years of productive labor (Akinmoju *et al*., 2024) [5]. This premature loss of life also deprives families and communities of income, which can have long-term negative effects on economic stability and well-being. Furthermore, the economic impact extends to healthcare systems that are left to manage the long-term care needs of CVD survivors, such as those with heart failure or chronic disability following a stroke (Jiang and McCoy, 2020) [18]. The indirect costs of CVD are particularly pronounced when considering the long-term nature of many cardiovascular conditions. Additionally, CVD-related disabilities, such as the inability to perform daily activities or return to work, can lead to reduced quality of life and additional financial challenges for both patients and caregivers (Obi *et al*., 2023) [2].

The economic burden of CVD is not evenly distributed across the globe, with significant disparities in the costs between developed and developing economies. In high-income countries, the direct costs of CVD are disproportionately high due to the advanced healthcare infrastructure, technological advancements, and the high cost of medical treatments (Uwumiro *et al*., 2023) [34]. Developed nations often have well-established healthcare systems that provide extensive diagnostic, surgical, and post-operative care. As a result, the financial burden of CVD is largely borne by public healthcare systems and private insurance companies, which often lead to higher overall costs for both the individual and society. In contrast, developing economies face unique challenges in managing the economic burden of CVD. While the prevalence of risk factors such as smoking, hypertension, and diabetes is increasing in many low- and middle-income countries, access to timely diagnosis and treatment remains limited due to inadequate healthcare infrastructure and resources. As a result, individuals in these regions often face higher rates of undiagnosed and untreated CVD, leading to higher rates of complications and premature mortality. Furthermore, the lack of access to advanced medical technologies and medications exacerbates the economic burden, as these countries struggle to provide essential care for their populations. Although the direct costs may be lower in developing economies due to the absence of advanced treatments and infrastructure, the indirect costs can be equally significant. The loss of productivity and premature mortality in these regions can have a devastating impact on the economy, especially in countries with limited social safety nets and high rates of poverty (Hone *et al*., 2019) [16]. The financial burden of CVD is exacerbated by the lack of preventative programs and public health education, which could mitigate the long-term costs of the disease.

The economic burden of cardiovascular disease is a complex and multifaceted issue that spans both direct and indirect costs. The high costs of healthcare services, medications, and hospitalizations, coupled with the loss of productivity and premature mortality, create significant financial challenges for individuals, healthcare systems, and economies (Schuver *et al*., 2024) [40]. While developed nations face a heavier burden due to advanced treatment costs, developing economies are not immune to the growing economic toll of CVD, particularly with limited healthcare resources and high rates of undiagnosed disease. Addressing the economic burden of CVD requires a comprehensive approach that includes both prevention and treatment strategies, with an emphasis on early detection, cost-effective interventions, and global health initiatives aimed at reducing risk factors and improving access to care (Zhu *et al*., 2020; Kapur and Hod, 2020) [49].

2.2 Early Detection Programs for Cardiovascular Disease

Cardiovascular disease (CVD) remains one of the leading causes of morbidity and mortality worldwide, posing a significant burden on global healthcare systems. Early detection of CVD is essential in reducing its impact, improving treatment outcomes, and lowering healthcare costs by addressing the disease in its early stages, before it leads to severe complications such as heart attacks, strokes, or heart failure (Ogieuhi *et al*., 2024) [5]. Early detection programs are instrumental in identifying individuals at high risk, enabling timely interventions and preventive strategies. These programs utilize various screening and diagnostic approaches, benefit from advancements in digital health and artificial intelligence (AI), and are closely linked to preventive measures that can help manage and reduce the risk of cardiovascular events.



Fig 1: Early detection programs

The foundation of early detection programs for CVD lies in the systematic screening and diagnostic evaluation of individuals at risk. The primary goal of these approaches is to identify individuals with risk factors for CVD, enabling early intervention and management. Among the most common screening tests for CVD risk are blood pressure measurements and cholesterol screenings (Uwumiro *et al*., 2024) [45]. Hypertension is a major risk factor for cardiovascular disease, often referred to as a "silent killer" because it typically has no noticeable symptoms. Regular blood pressure monitoring can help identify individuals who are at risk of developing heart disease or stroke, allowing for timely management through lifestyle changes and medications. Cholesterol screening, particularly measuring low-density lipoprotein (LDL) cholesterol and high-density lipoprotein (HDL) cholesterol, is another critical component of early detection. Elevated LDL cholesterol levels increase the risk of atherosclerosis, which can lead to heart attacks and strokes. Regular lipid panel testing provides valuable information about an individual's cardiovascular health and aids in assessing their need for cholesterol-lowering interventions (Brown *et al*., 2020) [12]. In addition to blood pressure and cholesterol screening, advanced imaging techniques such as echocardiograms, magnetic resonance imaging (MRI), and computed tomography (CT) scans are increasingly used to detect structural heart abnormalities, plaque buildup in arteries, and other markers of cardiovascular disease. These imaging modalities help healthcare providers assess the severity of existing conditions, identify asymptomatic disease, and monitor disease progression. Emerging diagnostic tools, such as biomarkers, are also playing a pivotal role in the early detection of CVD. Biomarkers are substances present in blood or other body fluids that can indicate the presence of disease. In the context of CVD, biomarkers like troponins, natriuretic peptides, and C-reactive protein (CRP) are used to assess heart damage, inflammation, and the risk of a cardiovascular event. The ability to detect these biomarkers in the early stages of disease can significantly improve the accuracy of diagnoses and the effectiveness of interventions. Advancements in digital health and artificial intelligence (AI) have revolutionized the landscape of early detection programs for CVD (Ugwuoke *et al*., 2024) [31]. Digital health technologies, including wearable devices and mobile health applications, allow for continuous monitoring of vital signs, such as heart rate, blood pressure, and activity levels, which are critical indicators of cardiovascular health. These devices can provide real-time data that not only assists individuals in managing their health but also allows healthcare providers to monitor patients remotely, intervening when necessary. AI and machine learning algorithms have further enhanced the ability to identify patterns and risk factors in large datasets, offering a more personalized and precise approach to early detection (Neupane *et al*., 2024) [28]. AI-driven tools can analyze complex data from electronic health records, genetic testing, imaging results, and wearable devices to predict the likelihood of developing cardiovascular diseases. AI models can recognize subtle changes in a patient's health data that may be difficult for clinicians to detect, leading to earlier identification of individuals at risk. AI has also enabled the development of predictive analytics tools that can assess the risk of cardiovascular events in real-time. These tools incorporate data from multiple sources, including medical history, lifestyle factors, and diagnostic results, to generate risk scores. By utilizing these technologies, healthcare providers can implement targeted preventive measures, offer personalized treatment plans, and reduce the incidence of severe cardiovascular outcomes (Wongvibulsin *et al*., 2019) [48].

Early detection of cardiovascular disease is closely linked to the implementation of preventive strategies that can reduce the progression of the disease and prevent adverse cardiovascular events. The most effective preventive strategies include lifestyle modifications, pharmacological interventions, and regular monitoring of risk factors (Koroma *et al*., 2024) [3]. Lifestyle modifications are often the first line of defense in managing cardiovascular risk. For individuals identified through early detection programs as being at high risk for CVD, interventions such as dietary changes, increased physical activity, smoking cessation, and stress management can significantly reduce the likelihood of developing heart disease. Public health campaigns and educational programs aimed at promoting heart-healthy behaviors can also help raise awareness about the importance of prevention and the role of early detection. Pharmacological interventions play a crucial role in the management of CVD risk factors. For individuals with elevated blood pressure, high cholesterol, or diabetes, medications such as antihypertensives, statins, and antidiabetic drugs can help control these conditions and prevent the onset of more severe cardiovascular events. Early initiation of these medications, based on the results of screening programs, can substantially reduce the incidence of heart attacks and strokes. Regular follow-up and monitoring are critical components of an effective preventive strategy. Once individuals are identified as being at high risk for cardiovascular disease, continuous monitoring of their health status, including blood pressure, cholesterol levels, and heart function, allows for timely adjustments to treatment plans and interventions. Additionally, the integration of digital health tools, such as mobile apps and remote monitoring devices, can enhance patient engagement and adherence to preventive measures (Solomon and Rudin, 2020) [41].

Early detection programs for cardiovascular disease are essential in mitigating the global burden of heart disease by identifying individuals at risk and enabling timely interventions (Obi *et al*., 2024) [5]. By utilizing screening and diagnostic approaches such as blood pressure and cholesterol monitoring, advanced imaging techniques, and biomarkers, healthcare providers can detect cardiovascular conditions before they lead to severe outcomes. The integration of digital health and AI technologies further enhances early detection efforts by providing continuous monitoring and predictive analytics. Finally, preventive strategies, including lifestyle modifications and pharmacological interventions, are critical in reducing the incidence of cardiovascular events

and improving overall public health (Aderinwale *et al*., 2024) [3]. Through the implementation of comprehensive early detection programs, healthcare systems can reduce mortality, improve quality of life, and alleviate the economic burden of cardiovascular disease.

2.3 Economic Benefits of Early Detection Programs

Early detection programs, particularly those targeting chronic diseases like cardiovascular disease (CVD), have the potential to yield substantial economic benefits. These programs not only improve patient outcomes but also reduce the financial burden on healthcare systems and society at large. By identifying health conditions in their early stages, when they are most treatable, early detection reduces long-term healthcare costs, lowers hospitalization and emergency care expenses, enhances workforce productivity, and fosters economic growth. A cost-benefit analysis of preventive versus reactive healthcare approaches further highlights the economic advantages of early detection (Efobi *et al*., 2024) [14].

Fig 2: Economic benefits of early detection programs

One of the most significant economic benefits of early detection programs is the reduction in long-term healthcare costs. When diseases are diagnosed early, interventions can be implemented at a stage when they are more cost-effective and less complex. Additionally, early detection can prevent complications that would otherwise require high-cost interventions, including emergency room visits and critical care. By addressing health risks proactively, early detection programs allow healthcare systems to allocate resources more efficiently, ultimately reducing the overall financial strain on both public and private healthcare systems.

Early detection of diseases like CVD can significantly lower hospitalization and emergency care costs, which are often the most expensive aspects of healthcare. When diseases are detected late or when symptoms are ignored until they become acute, patients are more likely to require emergency medical attention, including hospitalization and surgery. For example, a heart attack or stroke, often resulting from untreated or undiagnosed risk factors such as high blood pressure or cholesterol, typically leads to long hospital stays and intensive care, incurring high medical expenses. By contrast, early detection allows for the identification of at-risk individuals before they experience acute episodes. This enables healthcare providers to manage their conditions through outpatient care, medications, and lifestyle adjustments, reducing the need for emergency interventions (Bidemi *et al*., 2024) [11]. Early detection programs can therefore reduce the incidence of severe events that require hospitalization, thereby decreasing healthcare expenditures and minimizing the strain on emergency care resources.

Beyond healthcare savings, early detection programs contribute to improved workforce productivity and broader economic growth. Chronic diseases like CVD, diabetes, and hypertension often lead to absenteeism and presenteeism in the workplace, as employees may take time off to manage their conditions or work while experiencing symptoms. In many cases, these diseases result in permanent disability, reducing the ability of affected individuals to participate fully in the workforce (Adenusi *et al*., 2024) [2].

By detecting diseases early, workers can receive timely treatment and make lifestyle changes that improve their overall health and productivity. Employees who are healthier and better able to manage their conditions are less likely to experience prolonged absences or reduced performance due to illness. This leads to increased productivity, fewer days lost to sickness, and greater job retention. As a result, businesses and industries benefit from a healthier and more engaged workforce, contributing to overall economic growth and stability.

A cost-benefit analysis of preventive (early detection) versus reactive healthcare approaches underscores the economic advantages of early diagnosis. While preventive measures often require upfront investments in screening programs, diagnostic tools, and healthcare infrastructure, these costs are far outweighed by the long-term savings. Studies consistently show that investing in preventive healthcare programs, including early detection, results in significant economic returns by reducing the need for expensive treatments and hospitalizations later on. The return on investment from early detection is compounded by the societal benefits of reduced disability, improved quality of life, and a healthier workforce. Additionally, early detection programs have the potential to save lives, preventing premature death and the associated loss of labor force contributions (Mbakop *et al*., 2024) [26]. In contrast, reactive healthcare systems, which focus on treating diseases after they have reached an advanced stage, often result in far higher costs. These costs include not only the direct expenses of treatment and hospitalization but also the indirect costs associated with reduced workforce productivity, premature mortality, and the need for long-term care. The economic benefits of early detection programs for cardiovascular disease and other chronic conditions are substantial. Early diagnosis and intervention reduce long-term healthcare costs by preventing the progression of diseases to more advanced and expensive stages. Furthermore, early detection minimizes hospitalization and emergency care costs while improving workforce productivity and contributing to overall economic growth. A comprehensive cost-benefit analysis reveals that the long-term savings from early detection and preventive measures far exceed the initial investments, making early detection a highly cost-effective strategy for improving public health and economic stability.

2.4 Challenges in Implementing Early Detection Programs

Early detection programs for cardiovascular disease (CVD) offer significant benefits in terms of reducing long-term healthcare costs and improving patient outcomes. However, despite their potential, the implementation of such programs faces several challenges. These include the initial investment and infrastructure requirements, issues surrounding accessibility and affordability, compliance and behavioral factors in at-risk populations, and the complexities of policy and regulatory considerations (Olatunji *et al*., 2024) [5].

Addressing these challenges is crucial for ensuring the effectiveness and sustainability of early detection initiatives. One of the primary challenges in implementing early detection programs is the substantial initial investment required for infrastructure and resources. Screening and diagnostic tools for CVD, such as advanced imaging technologies, laboratory tests for biomarkers, and blood pressure monitoring systems, necessitate significant capital expenditures. Moreover, the deployment of such programs requires the establishment or enhancement of healthcare facilities, trained personnel, and ongoing maintenance of medical equipment. In addition to financial costs, the logistical challenges of integrating new technologies and services into existing healthcare systems can be substantial (Uwumiro *et al*., 2024) [46]. These barriers can delay the implementation of early detection programs, especially in resource-constrained settings, where healthcare systems may already be under strain due to competing demands.



Fig 3: Technological factors in challenges and barriers to cost-effective early detection

A major barrier to the successful implementation of early detection programs, particularly in low-income regions, is the issue of accessibility and affordability. Many of the diagnostic tools used for early detection, such as blood tests, imaging devices, and even basic blood pressure measurements, can be prohibitively expensive for underserved populations. In regions with limited healthcare budgets, the high cost of diagnostic technologies and screening programs often means that these services are unavailable to large portions of the population, particularly in rural or economically disadvantaged areas. Furthermore, even if these programs are made available, issues related to health insurance coverage, out-of-pocket expenses, and socioeconomic factors can make it difficult for individuals to access early detection services (Sriram and Khan, 2020) [42]. Without adequate financial support or subsidies, early detection programs may not reach those who are most in need, resulting in health disparities that undermine the efficacy of such initiatives.

Even when early detection programs are available, ensuring that at-risk populations comply with recommended screenings and follow-up care can be a significant challenge. Individuals at high risk for cardiovascular disease, such as those with a family history of heart disease, obesity, or diabetes, may be reluctant to participate in screening programs due to factors such as fear, lack of awareness, or low health literacy. Behavioral factors, such as resistance to medical advice or a lack of understanding about the importance of early detection, can lead to non-compliance with screening recommendations. Additionally, at-risk populations may face barriers in adhering to lifestyle changes or medical treatments recommended following early detection, such as modifications to diet, exercise, or medication regimens (Rippe and Angelopoulos, 2019) [37]. Overcoming these barriers requires not only effective communication and education strategies but also the engagement of healthcare providers, community leaders, and public health organizations to ensure that at-risk individuals understand the value of early detection and are motivated to participate in and adhere to recommended interventions.

Implementing early detection programs on a large scale requires the development of appropriate policies and regulatory frameworks. These frameworks must address issues related to the standardization of screening protocols, the integration of new technologies into existing healthcare systems, and the protection of patient privacy and data. Ensuring the accuracy and reliability of diagnostic tests is also essential, as false positives or false negatives could undermine the effectiveness of early detection efforts. Moreover, regulatory approval for new diagnostic tools and treatments must be obtained, which can be a lengthy and costly process. In many cases, the regulatory environment may not be well-suited to fast-track the approval of innovative detection methods, such as those involving digital health technologies or artificial intelligence-based diagnostic tools (Jamali *et al*., 2020) [17]. Additionally, policies must address issues of data security and privacy, particularly with the increased use of digital health platforms and electronic health records in early detection programs. Without strong and clear policies that support the safe, equitable, and effective implementation of these programs, early detection efforts may face significant barriers to success. While early detection programs for cardiovascular disease offer significant potential for improving health outcomes and reducing long-term healthcare costs, their implementation is fraught with challenges. These challenges include the substantial initial investment and infrastructure requirements, accessibility and affordability concerns in low-income regions, compliance and behavioral factors in at-risk populations, and complex policy and regulatory considerations. To overcome these barriers, it is essential for governments, healthcare providers, and international organizations to collaborate on developing sustainable, accessible, and effective early detection programs that can reach the populations most in need (Chotchoungchatchai *et al*., 2020) [13]. Only by addressing these challenges can the full potential of early detection in reducing the global burden of cardiovascular disease be realized.

2.5 Case Studies and Real-World Examples

Cardiovascular disease (CVD) remains one of the leading causes of death and disability worldwide. As highlighted by numerous studies, early detection of CVD plays a critical role in preventing the progression of the disease and reducing associated healthcare costs. Several national and regional early detection initiatives have demonstrated the positive impact of early diagnosis on health outcomes, healthcare expenditure, and mortality rates. The success stories of these programs provide valuable insights into the effectiveness of early detection strategies and offer lessons for future interventions.

One of the most well-known and influential early detection programs is the Framingham Heart Study, which began in 1948. This study, conducted in Framingham, Massachusetts, USA, is a long-term, ongoing research initiative that has provided crucial data on the risk factors for cardiovascular disease. The Framingham Heart Study has contributed significantly to understanding the genetic, environmental, and lifestyle factors that increase the risk of CVD (Said *et al*., 2019) [39]. The study's data has formed the basis for numerous cardiovascular risk prediction models, including the Framingham Risk Score, which is widely used in clinical practice to assess the risk of heart disease in individuals. Another notable initiative is the NHS Health Check in the United Kingdom, which is aimed at adults aged 40-74 years. This program offers a health check every five years, assessing risk factors for heart disease, stroke, kidney disease, and diabetes. The NHS Health Check includes a comprehensive screening process, including blood pressure measurements, cholesterol testing, and assessments of lifestyle behaviors. This program has proven effective in identifying individuals at risk of CVD and facilitating early intervention. In 2019, the program screened over 15 million people, resulting in significant numbers of referrals for treatment and lifestyle modifications. The success of such national programs demonstrates how structured early detection initiatives can reduce the incidence of CVD and improve public health outcomes.

Several real-world examples of successful early detection programs have shown their capacity to reduce both CVD-related costs and mortality rates. For instance, the American Heart Association's (AHA) Check. Change. Control. Cholesterol Program is an initiative aimed at reducing cholesterol levels in at-risk individuals. By promoting awareness and providing educational resources for blood pressure and cholesterol management, the program has successfully reduced hospitalizations related to cardiovascular events and lowered healthcare costs. A study published in the *American Journal of Preventive Medicine* in 2019 showed that individuals participating in the AHA's program had lower hospitalization rates and healthcare expenses due to better management of cholesterol levels. In the case of the National Health Insurance Scheme (NHIS) in South Korea, a program implemented in 2000, early detection of cardiovascular disease has been a key focus. By integrating CVD screening into routine healthcare services for insured individuals, the program has shown a reduction in the incidence of stroke and heart attacks over the past two decades. A 2017 study found that the NHIS screening program led to a decrease in stroke-related healthcare costs by 32% and a 20% reduction in mortality due to heart disease. The success of the NHIS highlights the economic and health benefits of universal access to preventive health services, demonstrating the potential for national-scale early detection programs to improve public health outcomes while also reducing healthcare expenditures (Qoronfleh, 2020; Mayston *et al*., 2020) [36].

The case studies above offer important lessons for the implementation of successful early detection programs. A key takeaway is the importance of accessible and systematic screening. Programs like the NHS Health Check and the NHIS have demonstrated that making screening services easily accessible to a wide population, particularly at-risk groups, leads to more individuals being diagnosed early and receiving timely interventions. Another lesson is the value of public health education and awareness. Programs like the AHA's Check. Change. Control. Cholesterol initiative have shown that educating the public about the risks of CVD and the importance of regular screening can empower individuals to take proactive steps in managing their cardiovascular health. In turn, this results in better long-term health outcomes and reduced healthcare utilization. Integration of digital health technologies and AI-based tools is emerging as an essential component of successful early detection programs. The use of wearable devices, health apps, and digital monitoring systems allows for continuous monitoring of health metrics like blood pressure, heart rate, and cholesterol levels. Such technologies enhance the efficiency of early detection programs by enabling real-time tracking and follow-up care, making it easier for both patients and healthcare providers to monitor progress and intervene when necessary. The case studies and real-world examples of early detection initiatives like the Framingham Heart Study, NHS Health Check, and NHIS demonstrate the substantial benefits of identifying cardiovascular disease risk factors early. These programs have successfully reduced the burden of CVD-related healthcare costs, decreased mortality rates, and improved patient outcomes. Key lessons from these successes emphasize the importance of accessible, systematic screening, public health education, and the integration of digital health tools in ensuring the effectiveness of early detection programs. Moving forward, these lessons can inform the development of more widespread, cost-effective, and efficient cardiovascular disease prevention strategies globally.

2.6 Future Directions and Policy Recommendations

Cardiovascular disease (CVD) remains a leading cause of morbidity and mortality globally. Early detection of CVD can significantly reduce its burden by enabling timely intervention, reducing healthcare costs, and improving patient outcomes (Rossello *et al*., 2019) [38]. However, several challenges remain in implementing widespread, effective early detection programs. Addressing these challenges requires innovative approaches, policy changes, and collaboration between public and private sectors.

One of the most pressing issues in the global fight against CVD is expanding access to screening and preventive care, especially in low- and middle-income regions. Many at-risk populations are not screened due to geographical, financial, or social barriers. Expanding access to screening services is essential to identify individuals at risk before the onset of clinical symptoms. This requires the development of infrastructure, particularly in underserved areas, and innovative models for delivering care. For example, mobile health clinics, telemedicine, and home-based diagnostic tools can help bridge the gap in access. Governments and health organizations should invest in these models to ensure early detection reaches vulnerable populations and to avoid the long-term costs associated with untreated cardiovascular diseases.

Public-private partnerships (PPPs) play a crucial role in financing and scaling up early detection programs. Governments alone often lack the financial resources to implement national or global programs at scale. Collaborative efforts between the public and private sectors can harness the strengths of both to improve cardiovascular health. Private companies, particularly those in the health technology and pharmaceutical sectors, can provide resources, research, and innovations to enhance the effectiveness of early detection tools (Martinez *et al*., 2023) [22]. Furthermore, private sector involvement can bring efficiencies, such as cost reductions through economies of scale. Policy initiatives should incentivize such partnerships by providing regulatory support, financial incentives, and

opportunities for collaboration between governments, health organizations, and the private sector.

The future of cardiovascular disease detection lies in the advancement of technological innovations and AI-driven predictive models. Machine learning algorithms and artificial intelligence (AI) have the potential to revolutionize early detection by improving risk prediction, personalizing care, and enhancing diagnostic accuracy. AI models can analyze large volumes of data from multiple sources, such as electronic health records, wearable devices, and genetic data, to identify at-risk individuals with high precision (Ahmed *et al*., 2020) [4]. This enables healthcare providers to intervene earlier, potentially before symptoms even appear. Technological advancements such as AI-powered imaging, telemedicine, and remote monitoring can also increase the efficiency and accessibility of early detection programs (Zoppo *et al*., 2020) [50]. These innovations can particularly benefit rural and low-resource settings where traditional diagnostic infrastructure may be limited. Governments and health organizations must prioritize research and development in AI technologies and integrate them into national early detection programs to optimize the early identification of CVD risks.

For early detection programs to be effective and sustainable, policy frameworks must ensure that healthcare investments are made with long-term goals in mind. Governments should allocate sufficient funds to healthcare, prioritizing preventive care and early detection as a key component of the national health agenda. This investment should be viewed not as an expense but as a long-term saving through the reduction of costly treatments, hospitalizations, and premature mortality. Additionally, policies should support the integration of early detection into primary healthcare systems, making it a routine part of check-ups for all adults, especially those over 40 (Fang *et al*., 2020) [15]. Policies should also focus on training healthcare professionals to deliver early detection services and interpret diagnostic results accurately. Furthermore, health policies must promote health equity by ensuring that underserved populations, including those in rural and low-income areas, have access to early detection services. This could be achieved by developing programs that focus on the specific needs of these populations, such as subsidized screening programs or the deployment of mobile health units. International cooperation and policy coordination are necessary to address global health disparities. By aligning strategies and pooling resources, countries can more effectively combat the global cardiovascular burden. Collaboration with international health organizations, such as the World Health Organization (WHO), can help standardize early detection protocols and facilitate knowledge sharing across countries (Kalkman *et al*., 2019) [19].

The future of early detection programs for cardiovascular disease lies in expanding access, fostering public-private partnerships, leveraging technological innovations, and ensuring sustainable investment through effective policy frameworks. By prioritizing these strategies, healthcare systems can improve outcomes for individuals at risk of CVD, reduce the economic burden of the disease, and enhance global health equity. Policymakers, healthcare providers, and the private sector must work together to address these challenges, ensuring that early detection programs are accessible, effective, and sustainable for future generations (Sun and Medaglia, 2019; Nuhu *ss*., 2020) [43].

3. Conclusion

Cardiovascular disease (CVD) remains a leading global health challenge, contributing significantly to morbidity, mortality, and economic burden worldwide. Early detection is a crucial strategy in reducing these impacts, as it allows for timely intervention, preventing the progression of the disease and improving patient outcomes. This explored the economic burden of CVD, early detection methods, and the role of preventive strategies in mitigating the long-term costs associated with CVD.

Key findings reveal that early detection programs can substantially reduce long-term healthcare costs by identifying at-risk individuals before the onset of clinical symptoms, leading to fewer hospitalizations and emergency care visits. Technologies like AI-driven predictive models and advanced diagnostic tools can further enhance early identification, especially when integrated into existing healthcare systems. Moreover, public-private partnerships and sustainable investment in screening infrastructure are essential to making these programs accessible across diverse populations, particularly in low-income regions.

Investing in early detection programs offers significant long-term economic benefits. By focusing on prevention, healthcare systems can reduce the costly burden of treating advanced CVD, improve workforce productivity, and enhance economic growth. The cost-benefit analysis supports the notion that preventive care is not only more cost-effective but also yields better patient outcomes, reducing mortality and improving quality of life. Governments and healthcare organizations must continue to invest in research, policy, and infrastructure to support early detection initiatives. Ultimately, sustainable and proactive healthcare strategies will be key to reducing the global burden of cardiovascular disease and improving public health outcomes worldwide.

4. Reference

1. Adegoke SA, Oladimeji OI, Akinlosotu MA, Akinwumi AI, Matthew KA. HemoTypeSC point-of-care testing shows high sensitivity with alkaline cellulose acetate hemoglobin electrophoresis for screening hemoglobin SS and SC genotypes. Hematol Transfus Cell Ther. 2022;44(3):341-5.
2. Adenusi A, Obi E, Asifat O, Magacha H, Ayinde A, Changela M. S843 Social Determinants of Therapeutic Endoscopy and Procedure Time in Patients With Acute Upper Gastrointestinal Bleeding. Am J Gastroenterol. 2024;119(10S):S581.
3. Aderinwale O, Zheng S, Mensah EA, Boateng I, Koroma FB, Nwajiugo RC, *et al*. Sociodemographic and behavioral determinants of cervical cancer screening among adult women in the United States. [Journal Name Missing]. 2024.
4. Ahmed Z, Mohamed K, Zeeshan S, Dong X. Artificial intelligence with multi-functional machine learning platform development for better healthcare and precision medicine. Database (Oxford). 2020;2020:baaa010.
5. Akinmoju OD, Olatunji G, Kokori E, Ogieuhi IJ, Babalola AE, Obi ES, *et al*. Comparative efficacy of continuous positive airway pressure and antihypertensive medications in obstructive sleep apnea-related hypertension: A narrative review. High Blood Press Cardiovasc Prev. 2024;[Online ahead of print]:1-11.
6. Al Hasan SM, Matthew KA, Toriola AT. Education and mammographic breast density. Breast Cancer Res Treat. 2024;[Online ahead of print]:1-8.
7. Avwioroko A, Ibegbulam C. Contribution of consulting firms to renewable energy adoption. Int J Phys Sci Res. 2024;8(1):17-27.
8. Avwioroko A. Biomass gasification for hydrogen

production. Eng Sci Technol J. 2023;4(2):56-70.
9. Avwioroko A. The integration of smart grid technology with carbon credit trading systems: Benefits, challenges, and future directions. Eng Sci Technol J. 2023;4(2):33-45.
10. Avwioroko A. The potential, barriers, and strategies to upscale renewable energy adoption in developing countries: Nigeria as a case study. Eng Sci Technol J. 2023;4(2):46-55.
11. Bidemi AI, Oyindamola FO, Odum I, Stanley OE, Atta JA, Olatomide AM, *et al*. Challenges facing menstruating adolescents: A reproductive health approach. [Journal Name Missing]. 2024.
12. Brown RE, Welsh P, Logue J. Systematic review of clinical guidelines for lipid lowering in the secondary prevention of cardiovascular disease events. Open Heart. 2020;7(2):e001396.
13. Chotchoungchatchai S, Marshall AI, Witthayapipopsakul W, Panichkriangkrai W, Patcharanarumol W, Tangcharoensathien V. Primary health care and sustainable development goals. Bull World Health Organ. 2020;98(11):792.
14. Efobi CC, Nri-ezedi CA, Madu CS, Obi E, Ikediashi CC, Ejiofor O. A retrospective study on gender-related differences in clinical events of sickle cell disease: A single centre experience. Trop J Med Res. 2023;22(1):137-44.
15. Fang EF, Xie C, Schenkel JA, Wu C, Long Q, Cui H, *et al*. A research agenda for ageing in China in the 21st century: Focusing on basic and translational research, long-term care, policy and social networks. Ageing Res Rev. 2020;64:101174.
16. Hone T, Mirelman AJ, Rasella D, Paes-Sousa R, Barreto ML, Rocha R, Millett C. Effect of economic recession and impact of health and social protection expenditures on adult mortality: A longitudinal analysis of 5565 Brazilian municipalities. Lancet Glob Health. 2019;7(11):e1575-83.
17. Jamali SH, Cockram J, Hickey LT. Is plant variety registration keeping pace with speed breeding techniques? Euphytica. 2020;216(8):131.
18. Jiang DH, McCoy RG. Planning for the post-COVID syndrome: how payers can mitigate long-term complications of the pandemic. J Gen Intern Med. 2020;35:3036-9.
19. Kalkman S, Mostert M, Gerlinger C, van Delden JJ, van Thiel GJ. Responsible data sharing in international health research: a systematic review of principles and norms. BMC Med Ethics. 2019;20:1-13.
20. Kapur A, Hod M. Maternal health and non-communicable disease prevention: An investment case for the post-COVID-19 world and need for better health economic data. Int J Gynaecol Obstet. 2020;150(2):151-8.
21. Koroma F, Aderinwale OA, Obi ES, Campbell C, Itopa MO, Nwajiugo RC, *et al*. Socio-demographic and behavioral predictors of depression among veterans in the USA. [Journal Name Missing]. 2024.
22. Martinez B, Reaser JK, Dehgan A, Zamft B, Baisch D, McCormick C, *et al*. Technology innovation: advancing capacities for the early detection of and rapid response to invasive species. Biol Invasions. 2020;22(1):75-100.
23. Matthew KA, Getz KR, Jeon MS, Luo C, Luo J, Toriola AT. Associations of vitamins and related cofactor metabolites with mammographic breast density in premenopausal women. J Nutr. 2024;154(2):424-34.
24. Matthew KA, Vanapali GK, Getz KR, Jeon MS, Luo C, Guo X, *et al*. Steroid hormone metabolites and mammographic breast density in premenopausal women. Cancer Res. 2024;84(6 Suppl):4431-1.
25. Mayston R, Ebhohimen K, Jacob K. Measuring what matters–information systems for management of chronic disease in primary healthcare settings in low and middle-income countries: challenges and opportunities. Epidemiol Psychiatr Sci. 2020;29:e127.
26. Mbakop RNS, Forlemu AN, Ugwu C, Soladoye E, Olaosebikan K, Obi ES, *et al*. Racial differences in non-variceal upper gastrointestinal (GI) bleeding: A nationwide study. Cureus. 2024;16(6).
27. Mela A, Rdzanek E, Poniatowski ŁA, Jaroszyński J, Furtak-Niczyporuk M, Gałązka-Sobotka M, *et al*. Economic costs of cardiovascular diseases in Poland: Estimates for 2015–2017 years. Front Pharmacol. 2020;11:1231.
28. Neupane H, Ahuja M, Ghimire A, Itopa MO, Osei PA, Obi ES. Excessive alcohol consumption and increased risk of heart attack. [Journal Name Missing]. 2024.
29. Nnagha EM, Ademola MK, Izevbizua EA, Uwishema O, Nazir A, Wellington J. Tackling sickle cell crisis in Nigeria: The need for newer therapeutic solutions in sickle cell crisis management–short communication. Ann Med Surg (Lond). 2023;85(5):2282-6.
30. Nuhu S, Mpambije CJ, Ngussa K. Challenges in health service delivery under public-private partnership in Tanzania: Stakeholders' views from Dar es Salaam region. BMC Health Serv Res. 2020;20:1-12.
31. Obi E, Aderinwale OA, Ugwuoke U, Okam O, Magacha H, Itopa MO. Evaluating and improving patient and family satisfaction with hemato-oncological services at an outpatient clinic in East Tennessee: A service excellence initiative. [Journal Name Missing]. 2024.
32. Obi ES, Devdat LNU, Ehimwenma NO, Tobalesi O, Iklaki W, Arslan F. Immune thrombocytopenia: A rare adverse event of vancomycin therapy. Cureus. 2023;15(5).
33. Ogieuhi IJ, Callender K, Odukudu GDO, Obi ES, Muzofa K, Babalola AE, *et al*. Antisense oligonucleotides in dyslipidemia management: A review of clinical trials. High Blood Press Cardiovasc Prev. 2024;[Online ahead of print]:1-15.
34. Okpujie VO, Uwumiro FE, Bojerenu M, Alemenzohu H, Obi ES, Chigbu NC, *et al*. Increased ventilator utilization, ventilator-associated pneumonia, and mortality in non-COVID patients during the pandemic. Baylor Univ Med Cent Proc. 2024;37(2):230-8.
35. Olatunji G, Kokori E, Ogieuhi IJ, Abraham IC, Olanisa O, Nzeako T, *et al*. Can CSL-112 revolutionize atherosclerosis treatment? A critical look at the evidence. Curr Probl Cardiol. 2024;102680.
36. Qoronfleh MW. Pathway to excellence in cancer care: Learning from Qatar's experience. Precis Med Sci. 2020;9(2):51-61.
37. Rippe JM, Angelopoulos TJ. Lifestyle strategies for risk factor reduction, prevention and treatment of cardiovascular disease. Lifestyle Med (3rd Ed.). 2019;19-36.
38. Rossello X, Dorresteijn JA, Janssen A, Lambrinou E, Scherrenberg M, Bonnefoy-Cudraz E, *et al*. Risk prediction tools in cardiovascular disease prevention: A report from the ESC Prevention of CVD Programme. Eur J Prev Cardiol. 2019;26(14):1534-44.
39. Said MA, Van De Vegte YJ, Zafar MM, Van Der Ende MY, Raja GK, Verweij N, *et al*. Contributions of interactions between lifestyle and genetics on coronary

artery disease risk. Curr Cardiol Rep. 2019;21:1-8.
40. Schuver T, Sathiyaseelan T, Ukoha N, Annor E, Obi E, Karki A, *et al*. Excessive alcohol consumption and heart attack risk. Circulation. 2024;150(Suppl 1):A4146639.
41. Solomon DH, Rudin RS. Digital health technologies: Opportunities and challenges in rheumatology. Nat Rev Rheumatol. 2020;16(9):525-35.
42. Sriram S, Khan MM. Effect of health insurance program for the poor on out-of-pocket inpatient care cost in India: Evidence from a nationally representative cross-sectional survey. BMC Health Serv Res. 2020;20:1-21.
43. Sun TQ, Medaglia R. Mapping the challenges of artificial intelligence in the public sector: Evidence from public healthcare. Gov Inf Q. 2019;36(2):368-83.
44. Ugwuoke U, Okeke F, Obi ES, Aguele B, Onyenemezu K, Shoham DA. Assessing the relationship between sleep duration and the prevalence of chronic kidney disease among veterans in the United States: A 2022 BRFSS cross-sectional study. [Journal Name Missing]. 2024.
45. Uwumiro F, Anighoro SO, Ajiboye A, Ndulue CC, Goddowell OO, Obi ES, *et al*. Thirty-day readmissions after hospitalization for psoriatic arthritis. Cureus. 2024;16(5).
46. Uwumiro F, Bojerenu MM, Obijuru CN, Osiogo EO, Ufuah OD, Obi ES, *et al*. Rates and predictors of contrast-associated acute kidney injury following coronary angiography and intervention, 2017–2020 US hospitalizations. SSRN Electron J. 2024;4793659.
47. Uwumiro F, Nebuwa C, Nwevo CO, Okpujie V, Osemwota O, Obi ES, *et al*. Cardiovascular event predictors in hospitalized chronic kidney disease (CKD) patients: A nationwide inpatient sample analysis. Cureus. 2023;15(10).
48. Wongvibulsin S, Martin SS, Steinhubl SR, Muse ED. Connected health technology for cardiovascular disease prevention and management. Curr Treat Options Cardiovasc Med. 2019;21:1-15.
49. Zhu Y, Swanson KM, Rojas RL, Wang Z, Sauver JLS, Visscher SL, *et al*. Systematic review of the evidence on the cost-effectiveness of pharmacogenomics-guided treatment for cardiovascular diseases. Genet Med. 2020;22(3):475-86.
50. Zoppo G, Marrone F, Pittarello M, Farina M, Uberti A, Demarchi D, *et al*. AI technology for remote clinical assessment and monitoring. J Wound Care. 2020;29(12):692-706.